Bicycle Therapeutics (NASDAQ:BCYC) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Bicycle Therapeutics (NASDAQ:BCYC) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Needham & Company LLC cut their price target on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Jefferies Financial Group restated a “buy” rating and issued a $10.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 29th. Finally, Zacks Research lowered Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bicycle Therapeutics has an average rating of “Hold” and an average target price of $13.57.

Bicycle Therapeutics Trading Down 2.3%

Shares of BCYC stock traded down $0.08 during trading hours on Friday, hitting $3.37. The company’s stock had a trading volume of 604,366 shares, compared to its average volume of 408,886. The business has a fifty day moving average of $3.70 and a 200-day moving average of $4.42. The stock has a market cap of $236.20 million, a price-to-earnings ratio of -1.66 and a beta of 1.59. Bicycle Therapeutics has a twelve month low of $3.26 and a twelve month high of $7.83.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.25. Bicycle Therapeutics had a negative return on equity of 26.02% and a negative net margin of 169.75%. The firm had revenue of $34.06 million during the quarter, compared to the consensus estimate of $12.22 million. On average, equities analysts expect that Bicycle Therapeutics will post -2.11 EPS for the current fiscal year.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently bought and sold shares of the company. Marshall Wace LLP grew its stake in Bicycle Therapeutics by 4.8% in the 3rd quarter. Marshall Wace LLP now owns 835,862 shares of the company’s stock worth $3,076,000 after acquiring an additional 37,922 shares during the period. Tocqueville Asset Management L.P. purchased a new position in shares of Bicycle Therapeutics during the 3rd quarter worth $142,000. 49 Wealth Management LLC purchased a new position in shares of Bicycle Therapeutics during the 3rd quarter worth $84,000. R Squared Ltd acquired a new stake in shares of Bicycle Therapeutics during the third quarter worth $98,000. Finally, Alps Advisors Inc. boosted its holdings in shares of Bicycle Therapeutics by 30.1% during the third quarter. Alps Advisors Inc. now owns 66,501 shares of the company’s stock worth $245,000 after purchasing an additional 15,379 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.